Search

The survival of acute myeloid leukaemia (AML) patients aged over 60 has been suboptimal historically, whether they are treated using hypomethylating agents, low-dose cytarabine (LDAC) or venetoclax-based regimens. Progress is being made, however, for subgroups with favourable molecular or cytogenetic findings. Arginine metabolism plays a key role in AML pathophysiology. We report the only randomised study of LDAC with recombinant arginase BCT-100 versus LDAC alone in older AML patients unsuitable for intensive therapy. Eighty-three patients were randomised to the study. An overall response rate was seen in 19.5% (all complete remission [CR]) and 15% (7.5% each in CR and CR without evidence of adequate count recovery [CRi]) of patients in the LDAC+BCT-100 and LDAC arms respectively (odds ratio 0.73, confidence interval 0.23-2.33; p = 0.592). No significant difference in overall or median survival between treatment arms was seen. The addition of BCT-100 to LDAC was well tolerated.

Single crystal studies provide a better understanding of the basic properties of organic photovoltaic devices. Therefore, in this work, rubrene single crystals with a thickness of 250 nm to 1000 nm were used to produce an inverted bilayer organic solar cell. Subsequently, polycrystalline rubrene (orthorhombic, triclinic) and amorphous bilayer solar cells of the same thickness as single crystals were studied to make comparisons across platforms. To investigate how single crystal, polycrystalline (triclinic-orthorhombic) and amorphous forms alter the charge carrier recombination mechanism at the rubrene/PCBM interface, light intensity measurements were carried out. The light intensity dependency of the J(SC), V-OC and FF parameters in organic solar cells with different forms of rubrene was determined. Monomolecular (Shockley Read Hall) recombination is observed in devices employing amorphous and polycrystalline rubrene in addition to bimolecular recombination, whereas the single crystal device is weakly affected by trap assisted SRH recombination due to reduced trap states at the donor acceptor interface. To date, the proposed work is the only systematic study examining transport and interface recombination mechanisms in organic solar cells produced by different structure forms of rubrene., Office of Naval Research [N0001416-1-2612, N000147-14-1-0053]; Turkey research fellowship [TUBITAK 2214/A-1059B141501315]; Turkey Scholarship Council [2214/A-1059B141501316]; 1003 -Primary Subjects R&D Funding Program [218M940], D. A. K. acknowledges the Turkey research fellowship (TUBITAK 2214/A-1059B141501315). K. K. thanks the Turkey Scholarship Council (2214/A-1059B141501316). B. G acknowledges the 1003 -Primary Subjects R&D Funding Program (218M940) and A. L. B. acknowledges the Office of Naval Research (N0001416-1-2612 and N000147-14-1-0053).

The prognosis for younger patients with relapsed acute myeloid leukaemia (AML) is generally dismal. Allogeneic stem cell transplantation is the preferred therapy for these patients. As part of the UK NCRI AML17 trial, daunorubicin/clofarabine (DClo) was compared with fludarabine, cytarabine, granulocyte colony-stimulating factor with idarubicin (FLAG-Ida) in 311 patients designated high-risk following course one of induction therapy, which has previously been reported. We now report the results of the same randomisation in patients who were refractory to two induction courses or subsequently relapsed. A total of 94 relapsed or refractory AML patients, usually less than 60 years of age and with mainly favourable or intermediate-risk cytogenetics, were randomised to receive up to three courses of DClo or FLAG-Ida, with the aim of proceeding to transplant. Complete remission was achieved in 74% of patients with no difference between the arms. Overall, 57% of patients received a transplant with no difference between the arms, likewise overall survival at five years showed no significant difference (21% for DClo vs. 22% for FLAG-Ida). No patient who did not receive a transplant survived beyond 21months. A stratified analysis including the 311 post course 1 high-risk patients who underwent the same randomisation showed a consistent treatment benefit for FLAG-Ida.